1. Baker, P. J., Hiernaux, J. R., Fauntleroy, M. B., Prescott, B., Cantrell, J. L., and Rudbach, J. A., 1988, Inactivation of suppressor T cell activity by nontoxic monophosphoryl lipid A (MPL). Infect. Immun. 56: 1076.
2. Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., Cantrell, J. L., and Zighelboim, J., 1985, Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Cancer Res. 45: 4215.
3. Cantrell, J. L., and Finn, D. J., 1988, Role of novel adjuvants in specific active immunotherapy, in: “Immunity to Cancer II,” M. S. Mitchell, ed. Alan R. Liss, New York.
4. Chase, J. J., Kubey, W., Dulek, M. H., Holmes, C. J., Salit, M. G., Pearson, III, F. C., and Ribi, E., 1986, Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect. Immun. 53: 711.
5. Freund, J., 1956, The mode of action of immunologic adjuvants, in: “Advances in Tuberculosis Research,” vol 7, H. Birkhauser and H. Bloch, eds. S. Krager, New York.